A Descriptive, Multicentre, Observational Epidemiological Study on Digestive Tumours

Status: Recruiting
Location: See location...
Study Type: Observational
SUMMARY

The aim of this observational study is to assess the current state of digestive tumours in Spain. By doing so, it seeks to enhance the quality of care, optimize the diagnosis and treatment of digestive tumours, and identify opportunities for improvement that can benefit patients. The study will investigate the epidemiological, biological, and clinical characteristics of digestive tumors diagnosed in patients aged 18 and older across healthcare centres in Spain. It also aims to generate knowledge and scientific evidence for events and situations that may impact on patients with digestive tumours (e.g. COVID-19 coronavirus pandemic). Furthermore, subject to the patient's consent, biological samples may be collected for use in translational research projects and for the identification of molecular markers that may be useful in healthcare decision-making.

Eligibility
Participation Requirements
Sex: All
Minimum Age: 18
Healthy Volunteers: f
View:

• Male and female patients ≥18 years old diagnosed with oesophageal cancer, gastric cancer, pancreatic cancer, hepatocarcinoma, gallbladder and bile duct cancer, cancer of the small intestine, appendix and gastrointestinal stroma, colorectal cancer, anal canal cancer or digestive hereditary cancer.

• Written informed consent available.

Locations
Other Locations
Spain
Grupo de Tratamiento de los Tumores Digestivos (TTD)
RECRUITING
Madrid
Contact Information
Primary
Esther Mahillo, PhD
ttd@ttdgroup.org
+34913788275
Time Frame
Start Date: 2020-12-23
Estimated Completion Date: 2030-12
Participants
Target number of participants: 20000
Treatments
Biliary Tract Cancer (BTC)
Patients diagnosed with cholangiocarcinoma or gallbladder carcinoma from 01-01-2017.
Hepatocellular Carcinoma (HCC)
Patients with hepatocellular carcinoma primary diagnosed from 01-01-2017 and treated with systemic therapy.
MSI-High Colorectal Cancer (MSI-H CRC)
Patients with MSI-High colorectal cancer (by PCR or IHQ) and primary pathological diagnosis from 01-01-2017.
Pancreatic Cancer
Patients with exocrine pancreatic cancer diagnosed from 01-01-2019.
Rectal Cancer
Patients diagnosed with rectal cancer from 01-01-2019.
Sponsors
Leads: Spanish Cooperative Group for the Treatment of Digestive Tumours (TTD)

This content was sourced from clinicaltrials.gov